lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 151 person Asked by .

bookmark_add

ENT Anaesthesia — Shared Airway, LASER Safety, Microlaryngoscopy & Post-Tonsillectomy Bleed Describe the principles and challenges of the "shared airway" in ENT anaesthesia [3]. Outline the LASER safety triad and anaesthetic management for microlaryngoscopy including jet ventilation [4]. Discuss the anaesthetic management of a child presenting with post-tonsillectomy haemorrhage [3].

collections Question Diagrams & Reference Images (1)

zoom_in View Image

description Clinical Response

" Q96 - ENT Anaesthesia — Shared Airway, LASER Safety, Microlaryngoscopy & Post-Tonsillectomy Bleed

Q96 · Paper II · 10 MARKS · Short Notes

ENT Anaesthesia — Shared Airway, LASER Safety, Microlaryngoscopy & Post-Tonsillectomy Bleed

Question: Describe the principles and challenges of the ""shared airway"" in ENT anaesthesia [3]. Outline the LASER safety triad and anaesthetic management for microlaryngoscopy including jet ventilation [4]. Discuss the anaesthetic management of a child presenting with post-tonsillectomy haemorrhage [3].

Core ConceptENT anaesthesia requires the surgeon and anaesthetist to share a single narrow airway. LASER surgery adds fire risk. Post-tonsillectomy haemorrhage is the classic ENT emergency – hypovolaemia, full stomach, and airway haemorrhage together.

A. The Shared Airway3 marks

Any airway device interferes with the surgical field; any surgical manoeuvre affects the airway – plan agreed before induction.
Options: microlaryngoscopy tube (5.0–5.5 mm), LASER-safe ETT, supraglottic device, jet ventilation, or THRIVE (apnoeic oxygenation via high-flow humidified nasal O₂, up to 70 L/min) for tubeless surgery.

B. LASER Safety & Microlaryngoscopy4 marks

Fire triad: Fuel (ETT/swabs) + Oxidiser (O₂/N₂O) + Ignition (LASER) – remove any one to prevent fire.
Prevention: LASER-safe ETT with saline-filled cuff; FiO₂ ≤0.30 (avoid N₂O entirely); lowest effective LASER power.
Fire management: STOP LASER → REMOVE ETT → FLOOD with saline → ventilate 100% O₂ → rigid bronchoscopy.
Jet ventilation: tubeless, unobstructed field; ETCO₂ unreliable – use ABG; CI: subglottic stenosis. TIVA mandatory (no ETT for volatile delivery).

C. Post-Tonsillectomy Haemorrhage3 marks

Primary (<24h, 0.5–1%) or secondary (days 5–10, 1–2%) haemorrhage; blood loss often underestimated (swallowed blood).
IV access + resuscitation first (crystalloid bolus, cross-match, correct coagulopathy).
This is a FULL STOMACH RSI – blood swallowed = high aspiration risk; atropine pre-induction; ketamine if hypovolaemic (or propofol if normovolaemic) + suxamethonium/rocuronium.
Have Yankauer suction ready; senior anaesthetist performs laryngoscopy; extubate awake, left lateral head-down (tonsil position).

Examiner's PearlLASER fire triangle: fuel+oxidiser+ignition – FiO₂ ≤0.30, avoid N₂O, LASER-safe tube. Jet ventilation: tubeless, ETCO₂ unreliable, CI=subglottic stenosis. Post-tonsillectomy bleed: full stomach + hypovolaemia – RSI mandatory, ketamine if hypovolaemic, extubate awake in tonsil position.

References: DAS Guidelines. AAGBI Laser Safety BS EN ISO 11553. Patel A, Nouraei SAR. Anaesthesia 2015;70:323-329. NAP4, RCOA 2011.

"

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 152 person Asked by .

bookmark_add

ICU Sedation and Analgesia — RASS, ABCDEF Bundle, CAM-ICU & Dexmedetomidine Describe the validated tools for assessing sedation depth and pain in the mechanically ventilated ICU patient [3]. Explain the concept of analgosedation, the ABCDEF bundle, and evidence-based sedation targets [4]. Discuss the pathophysiology of ICU delirium, its assessment using CAM-ICU, and the role of dexmedetomidine [3].

description Clinical Response

" Q97 - ICU Sedation and Analgesia — RASS, ABCDEF Bundle, CAM-ICU & Dexmedetomidine

Q97 · Paper II · 10 MARKS · Long Answer

ICU Sedation and Analgesia — RASS, ABCDEF Bundle, CAM-ICU & Dexmedetomidine

Question: Describe the validated tools for assessing sedation depth and pain in the mechanically ventilated ICU patient [3]. Explain the concept of analgosedation, the ABCDEF bundle, and evidence-based sedation targets [4]. Discuss the pathophysiology of ICU delirium, its assessment using CAM-ICU, and the role of dexmedetomidine [3].

Core ConceptDeep sedation is associated with prolonged ventilation, ICU-acquired weakness, delirium and excess mortality. Modern practice targets analgesia-first (analgosedation) with the lightest appropriate sedation (RASS −2 to 0).

A. Assessment Tools3 marks

Assessment	Tool	Notes
Sedation	RASS	−5 (unarousable) to +4 (combative); target −2 to −1
Pain	BPS / CPOT	For non-verbal patients; CPOT ≥3 = pain
NMB monitoring	TOF	Target 1–2 twitches if NMBAs used

B. Analgosedation & ABCDEF Bundle4 marks

Analgosedation: treat pain first (opioid infusion) before adding sedation – agitation is usually undertreated pain, not sedation deficiency.
Propofol preferred over midazolam (shorter, fewer active metabolites); dexmedetomidine as alternative.

ABCDEF	Element
A	Assess/prevent/manage pain
B	Both SAT + SBT daily (Girard 2008: ↓ventilator days, ↓1-yr mortality)
C	Choice of lightest effective sedation
D	Delirium: assess/prevent/manage
E	Early mobilisation
F	Family engagement

C. ICU Delirium, CAM-ICU & Dexmedetomidine3 marks

Delirium subtypes: hyperactive (~25%, visible), hypoactive (~50%, easily missed, worse outcome), mixed.
CAM-ICU positive = Feature 1 (acute/fluctuating) + Feature 2 (inattention) + EITHER Feature 3 (altered consciousness) OR Feature 4 (disorganised thinking).
Dexmedetomidine: selective α2-agonist – ""cooperative sedation"" without respiratory depression; MENDS2 (NEJM 2021): more delirium/coma-free days vs lorazepam; main side effect – bradycardia.

Examiner's PearlRASS −2 to 0 target for most ventilated patients. Analgosedation = pain first. ABCDEF: Assess pain→Both SAT+SBT→Choice of sedative→Delirium→Early mobility→Family. CAM-ICU: Features 1+2+(3 or 4). Dexmedetomidine: arousable sedation, MENDS2 – fewer delirium-days than lorazepam.

References: Barr J et al. Crit Care Med 2013;41:263-306. Devlin JW et al. Crit Care Med 2018;46:e825-e873. Girard TD et al. Lancet 2008;371:126-134. Pandharipande PP et al. NEJM 2021;384:1291-1302.

"

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 153 person Asked by .

bookmark_add

Major Trauma — ATLS ABCDE, Damage Control Resuscitation, TXA & Lethal Triad Outline the ATLS primary survey approach (ABCDE) and the initial airway management priorities in major trauma [3]. Describe the concept of permissive hypotension and damage control resuscitation (DCR) including the 1:1:1 ratio and tranexamic acid (CRASH-2) [4]. Define the lethal triad and explain how it perpetuates coagulopathy of trauma [3].

description Clinical Response

" Q98 - Major Trauma — ATLS ABCDE, Damage Control Resuscitation, TXA & Lethal Triad

Q98 · Paper II · 10 MARKS · Long Answer

Major Trauma — ATLS ABCDE, Damage Control Resuscitation, TXA & Lethal Triad

Question: Outline the ATLS primary survey approach (ABCDE) and the initial airway management priorities in major trauma [3]. Describe the concept of permissive hypotension and damage control resuscitation (DCR) including the 1:1:1 ratio and tranexamic acid (CRASH-2) [4]. Define the lethal triad and explain how it perpetuates coagulopathy of trauma [3].

Core ConceptA third of trauma deaths are potentially preventable. Damage control resuscitation targets haemostasis with blood products early, permits hypotension until surgical control, and uses TXA within 3 hours (CRASH-2 – 1.4% absolute mortality reduction).

A. ATLS Primary Survey (ABCDE)3 marks

Step	Priorities
A – Airway + C-spine	MILS (not traction); RSI if GCS≤8; surgical airway if CICO
B – Breathing	Needle thoracocentesis for tension pneumothorax; occlusive dressing for open chest wound
C – Circulation	Direct pressure/tourniquet, pelvic binder, FAST scan, blood products NOT crystalloid first
D – Disability	GCS, pupils, glucose
E – Exposure	Full exposure + log-roll, then cover and warm immediately

RSI in trauma: ketamine (haemodynamically stable, safe in TBI when airway controlled) + suxamethonium/rocuronium; MILS not traction.

B. Permissive Hypotension & DCR4 marks

Permissive hypotension: SBP 80–90 mmHg pre-haemostasis (aggressive crystalloid dislodges clot, dilutes factors, causes hypothermia/acidosis); exception – TBI: maintain MAP ≥80 mmHg.
1:1:1 ratio: pRBC:FFP:Platelets – PROPPR RCT (JAMA 2015): ↑haemostasis at 24h vs 1:1:2.
TXA (CRASH-2, Lancet 2010, n=20,211): 1g over 10 min then 1g over 8h → ↓all-cause mortality 1.5%; benefit ONLY if given within 3h of injury – harmful after 3h.
Damage control surgery: abbreviated surgery, pack, temporary closure, definitive repair 24–48h later.

C. The Lethal Triad3 marks

Component	Cause	Effect on Coagulation
Hypothermia	Exposure, cold fluids	↓enzyme activity, ↓platelet function; INR underestimates in-vivo coagulopathy
Acidosis	Hypoperfusion, saline	Thrombin generation ↓50% at pH 7.2
Coagulopathy (ATC)	Protein C activation + fibrinolysis; present in 25% on arrival	4× ↑mortality; self-perpetuating cycle

Examiner's PearlATLS ABCDE: treat life threats as found; MILS not traction. Permissive hypotension SBP 80–90 pre-haemostasis (TBI exception MAP≥80). DCR: 1:1:1 (PROPPR); TXA 1g within 3h (CRASH-2, harm after 3h). Lethal triad: hypothermia+acidosis+coagulopathy – self-perpetuating ""bloody vicious cycle"".

References: CRASH-2 Collaborators. Lancet 2010;376:23-32. Holcomb JB et al. JAMA 2015;313:471-482. Brohi K et al. J Trauma 2003;54:1127-1130. ATLS 10th Ed.

"

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 154 person Asked by .

bookmark_add

Ophthalmic Anaesthesia — Oculocardiac Reflex, IOP Control, Sub-Tenon's Block & Open Globe Describe the oculocardiac reflex (OCR) – its mechanism, clinical presentation, and management [3]. Explain the factors affecting intraocular pressure (IOP) and how anaesthetic agents alter IOP [3]. Outline the technique and complications of the sub-Tenon's block, and describe the anaesthetic management of a patient with an open globe injury [4].

collections Question Diagrams & Reference Images (2)

zoom_in View Image

description Clinical Response

" Q99 - Ophthalmic Anaesthesia — Oculocardiac Reflex, IOP Control, Sub-Tenon's Block & Open Globe

Q99 · Paper II · 10 MARKS · Short Notes

Ophthalmic Anaesthesia — Oculocardiac Reflex, IOP Control, Sub-Tenon's Block & Open Globe

Question: Describe the oculocardiac reflex (OCR) – its mechanism, clinical presentation, and management [3]. Explain the factors affecting intraocular pressure (IOP) and how anaesthetic agents alter IOP [3]. Outline the technique and complications of the sub-Tenon's block, and describe the anaesthetic management of a patient with an open globe injury [4].

Core ConceptThe oculocardiac reflex can produce life-threatening bradyarrhythmia. IOP management is critical in open globe injury, where RSI aspiration risk conflicts with minimising IOP rise. Modern consensus favours RSI with high-dose rocuronium (+sugammadex available).

A. Oculocardiac Reflex (OCR)3 marks

Mechanism: trigeminovagal reflex – extraocular muscle traction/globe pressure → short/long ciliary nerves → V1 → vagus → cardiac slowing.
Triggers: strabismus surgery (medial rectus traction), retrobulbar pressure/haemorrhage.
Presentation: bradycardia (commonest), junctional rhythm, AV block, VF (severe).
Management: stop traction immediately (usually resolves in 15–30s); atropine 20 mcg/kg IV if persists; glycopyrrolate preferred in elderly.

B. IOP — Determinants & Anaesthetic Effects3 marks

Factor	Effect on IOP
Succinylcholine	↑6–8 mmHg for 5–10 min (tonic muscle contraction)
Ketamine	↑IOP – avoid as sole agent in open globe
Propofol	↓IOP ~30–40% – safe in glaucoma/open globe
Volatile agents	↓IOP dose-dependently
Laryngoscopy/intubation	↑10–15 mmHg transiently – blunt with remifentanil
Coughing/Valsalva/PEEP	↑IOP via ↑episcleral venous pressure

C. Sub-Tenon's Block & Open Globe4 marks

Sub-Tenon's: blunt cannula into sub-Tenon space (inferonasal quadrant, 5–7 mm from limbus), inject 3–5 mL LA; no sharp needle near globe – safer than retrobulbar; chemosis expected/harmless; globe perforation rare (~1:16,000).
Open globe RSI: modern consensus – propofol + remifentanil + rocuronium 1.2 mg/kg (does NOT raise IOP, avoids the succinylcholine debate) with sugammadex immediately available; avoid positive-pressure mask ventilation; cricoid debated.
Antiemetic prophylaxis mandatory; extubate awake, smoothly, to avoid coughing/Valsalva raising IOP.

Examiner's PearlOCR: V1 afferent, vagus efferent – stop traction first, atropine 20 mcg/kg if persists. IOP: succinylcholine ↑6–8 mmHg; propofol ↓30–40%; laryngoscopy ↑10–15 mmHg. Sub-Tenon's: safest block, blunt cannula, inferonasal quadrant. Open globe: rocuronium 1.2 mg/kg + sugammadex ready = current consensus.

References: McGoldrick KE, Gayer SI. Miller's Anesthesia, 9th Ed. Pandey SK et al. Can J Ophthalmol 2007. Murphy DF. Anesth Analg 1985;64:520-530. NAP4, RCOA 2011.

"

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 155 person Asked by .

bookmark_add

TIVA & Future — TCI Models, Closed-Loop Anaesthesia & AI in Anaesthesia Explain the pharmacokinetic basis of target-controlled infusion (TCI) and compare the Marsh and Schnider models for propofol TCI [4]. Describe the clinical advantages and limitations of TIVA, including monitoring of anaesthetic depth [3]. Outline the concept of closed-loop anaesthesia and discuss future directions in anaesthetic delivery and monitoring [3].

description Clinical Response

" Q100 - TIVA & Future — TCI Models, Closed-Loop Anaesthesia & AI in Anaesthesia

Q100 · Paper II · 10 MARKS · Long Answer

TIVA & Future — TCI Models, Closed-Loop Anaesthesia & AI in Anaesthesia

Question: Explain the pharmacokinetic basis of target-controlled infusion (TCI) and compare the Marsh and Schnider models for propofol TCI [4]. Describe the clinical advantages and limitations of TIVA, including monitoring of anaesthetic depth [3]. Outline the concept of closed-loop anaesthesia and discuss future directions in anaesthetic delivery and monitoring [3].

Core ConceptTCI systems let the anaesthetist specify a target plasma or effect-site concentration; the pump calculates the infusion rate using a validated PK model. Closed-loop anaesthesia – where a depth monitor auto-adjusts the TCI – represents the frontier of anaesthetic delivery.

A. Pharmacokinetics of TCI — Marsh vs Schnider4 marks

Three-compartment model (central + 2 peripheral); pump solves differential equations to hit target concentration.
Effect-site (Ce): accounts for blood-brain equilibration delay (k_e0); effect-site TCI gives faster induction, less overshoot than plasma-targeted.

Parameter	Marsh (1991)	Schnider (1999)
V1 (central)	Scales with TBW (0.228 L/kg)	Fixed 4.27 L – risk of high initial Ce in obese/elderly
Target	Plasma (Cp)	Effect-site (Ce) always
k_e0	0.26 min&supminus;¹	0.456 min&supminus;¹ (faster equilibration)
Paediatric use	Not validated (Paedfusor used instead)	Not validated

B. TIVA — Advantages, Limitations & Depth Monitoring3 marks

Advantages: ↓PONV (propofol antiemetic), no theatre pollution, MH-safe, LASER airway fire safety, preserves MEPs for IONM, smooth emergence.
Limitations: awareness risk if IV access fails (NAP5: TIVA 1:8,600 vs volatile 1:15,000); PRIS risk with prolonged high-dose propofol.
Depth monitoring: BIS (target 40–60) or Entropy; ETCO₂ monitoring mandatory with TIVA + NMBDs (NAP5) to detect circuit disconnection.

C. Closed-Loop Anaesthesia & Future Directions3 marks

Closed-loop: BIS/entropy feeds back to a control algorithm (PID) that auto-adjusts TCI target – Liu N trials: ↓drug consumption, ↓time outside target, faster emergence.
Future directions: pharmacogenomics (CYP2B6/UGT1A9-guided dosing), exhaled propofol monitoring, AI-based Hypotension Prediction Index (HPI – predicts MAP<65 up to 15 min ahead, HYPE trial 2021).

Examiner's PearlTCI = PK model drives pump to target Cp/Ce. Marsh: V1 scales with weight, plasma-target. Schnider: fixed V1 4.27L, always effect-site, faster k_e0. TIVA advantages: ↓PONV, MH-safe, LASER-safe, preserves MEPs. NAP5: TIVA awareness 1:8,600 – BIS+ETCO₂ mandatory with NMBDs. Closed-loop: BIS feedback → auto-titration.

References: Marsh B et al. Br J Anaesth 1991;67:41-48. Schnider TW et al. Anesthesiology 1999;88:1170-1182. Liu N et al. Anesth Analg 2011;112:546-557. Cook TM et al. (NAP5) Anaesthesia 2014;69:1089-1101.

"

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 156 person Asked by .

bookmark_add

Discuss the physiological regulation of CBF, BBB structure/breakdown in neuro-trauma, ICP factors, ICP-lowering pharmacology, and SjO2 monitoring.

description Clinical Response

"

Q1 · PAPER I · 10 MARKS

Cerebral Blood Flow, Intracranial Pressure & the Monro-Kellie Doctrine

AIIMS · PAPER I — APPLIED BASIC SCIENCES [10 MARKS]

Discuss the physiological regulation of CBF, BBB structure/breakdown in neuro-trauma, ICP factors, ICP-lowering pharmacology, and SjO2 monitoring.

⚙ Core Concept

Normal CBF ~50 mL/100g/min (grey matter 80, white matter 20). CBF is held constant across MAP 60-150 mmHg by autoregulation (myogenic, metabolic, neurogenic, endothelial). Outside this range CBF becomes pressure-passive - the single most exam-relevant concept in neuroanesthesia.

A. Physiological Regulation of CBF

Mechanism	Basis	Clinical Relevance
Pressure autoregulation (myogenic)	Vascular smooth muscle constricts/dilates with transmural pressure (Bayliss effect)	Maintains flat CBF curve 60-150 mmHg; impaired in TBI, ischemia
Metabolic (flow-metabolism coupling)	CBF tracks CMRO2; adenosine, K+, H+ cause local vasodilation	Basis of functional imaging; burst-suppression reduces CBF
Chemical - PaCO2	CBF changes ~3-4%/mmHg PaCO2 (20-80 mmHg) via perivascular pH	Hyperventilation (PaCO2 30) acutely lowers ICP; effect wanes over 6-24h
Chemical - PaO2	Unchanged until PaO2 <50-60 mmHg, then steep vasodilation	Hypoxia is a potent, late-acting cerebral vasodilator
Neurogenic	Sympathetic/parasympathetic innervation of larger vessels	Minor role; modulates autoregulation curve
Endothelial	NO (dilator) vs endothelin-1 (constrictor) balance	Volatiles impair endothelial autoregulation dose-dependently

Autoregulation curve: flat plateau 60-150 mmHg -> below 60 pressure-passive ischemia risk -> above 150 forced dilation, vasogenic edema/hemorrhage risk. Curve shifts right in chronic hypertension and is lost/flattened in TBI, severe hypoxia, high volatile concentrations.

B. Blood-Brain Barrier - Structure & Breakdown

Endothelial tight junctions (claudin-5, occludin, ZO-1) - principal anatomical basis of BBB
Basement membrane - continuous, non-fenestrated
Pericytes - regulate permeability and angiogenesis
Astrocytic end-feet - ensheath >99% of capillary surface
Efflux transporters (P-glycoprotein) exclude lipophilic xenobiotics

Functional: permits small lipophilic molecules by diffusion; excludes ionized/polar molecules unless actively transported (GLUT-1, LAT-1).

BBB Breakdown in Acute Neuro-Trauma

Mechanical disruption of tight junctions + MMP-9 degradation of basement membrane -> vasogenic edema. Secondary cascade: glutamate excitotoxicity -> astrocyte swelling -> cytotoxic edema. Biphasic breakdown - immediate (mechanical) and delayed (4-6h, inflammatory) - the delayed phase is a therapeutic window for steroids/hyperosmolar agents.

C. Factors Influencing ICP & the Monro-Kellie Doctrine4 marks

Compartment	Compensatory Mechanism	Pathological Increase
CSF	Shunted to spinal subarachnoid space; increased reabsorption	Hydrocephalus, choroid plexus tumor
Blood	Venous compression/displacement (first, fastest buffer)	Venous sinus thrombosis, jugular compression, hypercapnia
Brain	Minimal - only via herniation (decompensation)	Tumor, edema, abscess

Normal ICP 5-15 mmHg (supine adult). CPP = MAP - ICP (or -CVP if higher). Target CPP in TBI: 60-70 mmHg (BTF).

Monro-Kellie Doctrine

Cranium is rigid/non-expansile. Total intracranial volume = Brain (80%) + CSF (10%) + Blood (10%) = constant. Increase in one compartment must be offset by another (CSF first, then venous blood) - once reserve is exhausted, the pressure-volume curve becomes exponential.

D. Pharmacological Strategies to Decrease Elevated ICP3 marks

Agent/Strategy	Mechanism	Practical Points
Mannitol 0.25-1 g/kg	Osmotic gradient draws water into vasculature	Onset 15-30min, lasts 90min-6h; needs intact BBB; risk rebound edema/AKI if osm >320
Hypertonic saline 3-23.4%	Osmotic effect without diuresis	Preferred if hypotensive/hypovolemic; monitor Na (avoid >160 or rapid correction)
Hyperventilation PaCO2 30-35	Hypocapnia -> vasoconstriction -> lower CBV	Temporizing only; avoid PaCO2 <25; reserve for impending herniation
Sedation (propofol/midazolam)	Lower CMRO2 -> lower CBF -> lower CBV	Watch hypotension/lower CPP
Barbiturate coma	Maximal CMRO2 reduction, burst suppression	Refractory ICP only; myocardial depression
Neuromuscular blockade	Prevents coughing/straining raising ICP	Adjunct only; masks seizures
Head-up 30 deg, neutral neck	Promotes jugular venous drainage	Avoid jugular compression from tight ETT ties
CSF drainage (EVD)	Direct volume removal	Most rapid, titratable ICP-lowering intervention
Decompressive craniectomy	Removes rigid-box constraint	Refractory ICP; improves survival (DECRA/RESCUEicp)

E. Continuous SjO2 Monitoring3 marks

Fiberoptic catheter retrogradely placed in the internal jugular vein (dominant side) with tip at the jugular bulb samples global cerebral venous oxygen saturation.

SjO2 Value	Interpretation
Normal 55-75%	Balanced CBF-CMRO2 coupling
<50% (desaturation)	Relative cerebral ischemia - inadequate CBF for demand
>75% (luxury perfusion)	Hyperemia OR reduced O2 extraction/mitochondrial failure

Limitation: global not regional - focal ischemia can be masked. Requires frequent co-oximetry calibration. Complements PbtO2 for regional data.

💬 Viva Corner

Q. What is the lower and upper limit of cerebral autoregulation?

MAP 60-150 mmHg in normotensive adults. Below 60: ischemia risk. Above 150: forced vasodilation, edema/hemorrhage risk. Curve shifts right in chronic hypertensives.

Q. Mannitol vs hypertonic saline in a hypotensive TBI patient?

Hypertonic saline - mannitol causes osmotic diuresis and can worsen hypovolemia/hypotension; HTS expands intravascular volume while reducing ICP.

★ Examiner's Pearl

Draw the autoregulation curve with numeric limits (60-150 mmHg). State Monro-Kellie quantitatively (80:10:10). For SjO2 always mention it is a global, not regional, measure.

References

Miller's Anesthesia 9th Ed Ch16/41. Brain Trauma Foundation Guidelines 4th Ed (2016). Smith M. Monitoring intracranial pressure (Anesth Analg 2008;106:240-248).

"

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 157 person Asked by .

bookmark_add

Functional anatomy of the NMJ; mechanism, metabolism, elimination kinetics, TOF/PTC-based dosing, and anaphylaxis/cardiac risk of Sugammadex.

description Clinical Response

"

Q2 · PAPER I · 10 MARKS

Neuromuscular Junction Anatomy & Clinical Pharmacology of Sugammadex

PGIMER · PAPER I — APPLIED BASIC SCIENCES [10 MARKS]

Functional anatomy of the NMJ; mechanism, metabolism, elimination kinetics, TOF/PTC-based dosing, and anaphylaxis/cardiac risk of Sugammadex.

⚙ Core Concept

Sugammadex is a modified gamma-cyclodextrin that reverses aminosteroid NMBs (rocuronium > vecuronium) by direct molecular encapsulation - not enzyme inhibition - allowing reversal of any depth of block, including immediate post-induction rescue.

A. Functional Anatomy of the NMJ

Component	Structure	Function
Presynaptic terminal	ACh vesicles (~10,000 molecules each), mitochondria, VG Ca2+ channels	AP -> Ca2+ influx -> vesicle fusion -> ACh release
Synaptic cleft	~50 nm gap; AChE anchored to basal lamina	ACh diffuses across; AChE terminates signal <1ms
Postsynaptic membrane	Junctional folds bearing nicotinic AChR at fold crests	ACh binding -> channel opens -> end-plate potential
Nicotinic AChR	Pentameric (2a,b,d,e - adult); 2 ACh must bind both alpha subunits	Basis of competitive antagonism by NDMRs

Large margin of safety - only 70-80% receptor occupancy needed to block transmission; ~75% must be blocked before twitch height visibly falls on TOF.

B. Mechanism - Encapsulation vs AChE Inhibition

Feature	Sugammadex (Encapsulation)	Neostigmine (AChE Inhibition)
Mechanism	Cyclodextrin forms 1:1 host-guest complex with rocuronium's steroid nucleus	Inhibits AChE -> raises ACh, out-competes NDMR
Selectivity	Aminosteroids only (roc>>vec>panc); ineffective vs benzylisoquinoliniums	Non-selective, effective on all NDMRs
Depth reversible	Any depth incl. profound block (PTC 1-2)	Only moderate block (>=2 TOF twitches)
Onset	Rapid 2-3 min even from deep block	Slower 10-15 min even from moderate block
Cholinergic effects	None	Bradycardia, bronchospasm, salivation - needs antimuscarinic
Ceiling effect	None within clinical doses	Yes - excess dose worsens block

C. Pharmacokinetics, Metabolism & Elimination

Distribution: Vd ~11-14 L
Metabolism: sugammadex itself is NOT metabolized, pharmacologically inert once bound
Elimination: free sugammadex and sugammadex-rocuronium complex eliminated almost entirely unchanged renally (>90% in 24h); t1/2 ~2h
Mechanism: encapsulation creates a concentration gradient drawing rocuronium from NMJ back to plasma (""Le Chatelier"")

Renal Impairment

Severe renal impairment (CrCl <30) markedly prolongs elimination of the complex - not recommended in dialysis/severe renal failure per several guidelines; use individualized.

D. Dosing Strategies (TOF/PTC)3 marks

Clinical Scenario	Depth of Block	Dose
Routine reversal	Reappearance of T2 on TOF	2 mg/kg IV
Deep block reversal	PTC 1-2 (no TOF response)	4 mg/kg IV
Immediate reversal	3 min after rocuronium 1.2 mg/kg (CICV rescue)	16 mg/kg IV

Endpoint of adequate reversal: quantitative TOF ratio >=0.9 on objective monitoring - tactile/visual assessment is unreliable above TOF 0.4.

E. Anaphylactic Risk & Cardiac Side Effects3 marks

Anaphylaxis: ~0.039-0.3% incidence (dose-dependent, higher with 16 mg/kg); NAP6 (UK) identified sugammadex as a significant trigger, can occur on first exposure
Cardiac: generally stable; bradycardia (including rare severe cases) - FDA warning to keep atropine available
Coagulation: mild transient aPTT/PT prolongation
Hormonal: transiently binds progesterone - advise additional contraception for 7 days

💬 Viva Corner

Q. Why can sugammadex reverse profound block when neostigmine cannot?

Neostigmine out-competes the relaxant via raised ACh but has a ceiling effect at profound block. Sugammadex physically removes rocuronium from circulation, independent of receptor occupancy.

Q. What is the objective endpoint for safe extubation after sugammadex?

Quantitative TOF ratio >=0.9 on an objective monitor - tactile/visual assessment cannot reliably distinguish TOF 0.4 from 0.9.

★ Examiner's Pearl

Contrast encapsulation vs AChE inhibition explicitly. Quote the three dosing scenarios (2/4/16 mg/kg) tied to TOF/PTC criteria, and mention NAP6 for anaphylaxis.

References

Naguib M. Sugammadex (Anesth Analg 2007;104:575-581). NAP6 Report, RCoA 2018. Hristovska AM et al. Cochrane 2017.

"

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 158 person Asked by .

bookmark_add

Physical gas laws governing the anesthesia circuit; working principles, compensation systems, pumping/back-pressure effects, and mis-filling hazards of variable-bypass vaporizers.

collections Question Diagrams & Reference Images (1)

zoom_in View Image

description Clinical Response

"

Q3 · PAPER I · 10 MARKS

Physical Laws of Gases/Vapors & Variable-Bypass Vaporizers

AIIMS · PAPER I — APPLIED BASIC SCIENCES [10 MARKS]

Physical gas laws governing the anesthesia circuit; working principles, compensation systems, pumping/back-pressure effects, and mis-filling hazards of variable-bypass vaporizers.

⚙ Core Concept

A variable-bypass vaporizer splits fresh gas flow between a bypass channel (never touches liquid) and a vaporizing chamber (saturated with agent vapor), recombining so the output equals the dial-set % regardless of FGF, within the design range (0.2-15 L/min).

A. Physical Gas Laws Relevant to the Circuit

Law	Statement	Anesthetic Application
Boyle's Law	P x V = k (constant T)	Cylinder pressure falls proportionally with O2 content; gas expands at altitude
Charles' Law	V/T = k (constant P)	Warmed gas reads falsely low flow on flowmeter
Gay-Lussac's Law	P/T = k (constant V)	Cylinder heating -> dangerous pressure rise; never apply external heat
Dalton's Law	Total pressure = sum of partial pressures	Vapor concentration is a partial-pressure phenomenon
Raoult's Law	Vapor pressure of a component prop. to mole fraction	Relevant to mixed liquid anesthetic contamination
Regnault/SVP principle	Liquid in closed space generates fixed SVP at given temp	Determines max achievable vapor concentration

B. Working Principle of a Variable-Bypass Vaporizer

FGF enters -> splits at splitting valve: (1) bypass flow (majority) and (2) vaporizing chamber flow (saturated over wicks) -> streams recombine downstream -> dial controls splitting ratio.

Wick system increases surface area for evaporation
Agent-specific keyed filling systems (Tec-fill, Saf-T-fill) prevent cross-filling
Concentration-calibrated (not flow-calibrated)
Located outside the circle system (VOC), interlocked against simultaneous use of >1 vaporizer

C. Temperature & Flow Compensation4 marks

As liquid vaporizes it absorbs latent heat -> chamber cools -> SVP falls -> output would decrease. Compensation:

Method	Mechanism
Bimetallic strip valve	Two metals with different expansion coefficients bend with temp, auto-adjusting splitting ratio
High thermal mass construction	Copper/brass body buffers temperature swings
Water bath jacket (older)	Surrounds chamber with water for thermal buffering

Flow compensation: modern vaporizers use flow-dependent, non-linear splitting ratios to maintain accurate output across 0.2-15 L/min.

D. Pumping Effect & Back-Pressure Effect3 marks

Phenomenon	Mechanism	Effect
Pumping effect	IPPV pressure waves retrograde into vaporizer compress bypass gas more than chamber gas; release surges saturated vapor out	Output increases unpredictably - worst at low FGF/low dial/older large-chamber vaporizers
Backpressure effect	O2 flush/downstream surges compress chamber gas	Increases vapor delivered on release

E. Hazards of Mis-filling or Tilting3 marks

Tilting/overturning: liquid can spill into bypass channel -> unpredictable concentrated bolus
Overfilling beyond max mark: same hazard
Underfilling: inadequate wick saturation -> falsely low output, awareness risk
Post-tilt protocol: take out of service, flush at high FGF/high setting with chamber isolated before reuse
Desflurane exception: needs an electrically heated, pressurized vaporizer (Tec 6), not simple variable-bypass

Mis-filling Hazard

Wrong agent filled -> dial delivers incorrect actual concentration (different SVP) -> overdose or awareness. Keyed filling systems are the primary safeguard.

💬 Viva Corner

Q. Why does the pumping effect increase vaporizer output?

Retrograde IPPV pressure pulses compress bypass gas more than the saturated chamber gas; on release a disproportionate vapor bolus exits. Worst at low FGF/low dial settings.

Q. Why is desflurane unsuitable for a conventional variable-bypass vaporizer?

Its very high SVP (~669 mmHg at 20C) and near-room-temperature boiling point make splitting unpredictable; requires an electrically heated, pressurized Tec 6 vaporizer.

★ Examiner's Pearl

Explain temperature compensation mechanistically (bimetallic strip + thermal mass). Tie pumping effect explicitly to IPPV and differential gas compressibility.

References

Dorsch JA, Dorsch SE. Understanding Anesthesia Equipment, 6th Ed Ch6. Andrews JJ. Miller's Anesthesia 9th Ed Ch26.

"

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 159 person Asked by .

bookmark_add

PK/PD of dexmedetomidine; receptor affinity, central sedative pathways, and cardiovascular/respiratory physiological impacts.

description Clinical Response

"

Q5 · PAPER I · 10 MARKS

Dexmedetomidine — Pharmacokinetics, Pharmacodynamics & Physiological Impacts

AIIMS · PAPER I — APPLIED BASIC SCIENCES [10 MARKS]

PK/PD of dexmedetomidine; receptor affinity, central sedative pathways, and cardiovascular/respiratory physiological impacts.

⚙ Core Concept

Dexmedetomidine is a highly selective alpha2-adrenergic agonist (alpha2:alpha1 ~1620:1) that produces sedation by hijacking the brain's natural sleep pathway (locus coeruleus -> VLPO) rather than acting on GABA receptors - explaining its ""cooperative/arousable sedation"" profile and lack of significant respiratory depression.

A. Receptor Affinity & Mechanism

Target: alpha2-adrenoceptors (alpha2A/2B/2C), Gi-coupled, lower cAMP
alpha2A: sedation, analgesia, sympatholysis (locus coeruleus, spinal cord)
alpha2B: initial vasoconstrictive hypertensive response, shivering suppression
alpha2C: cognitive/sensory modulation, startle response
Presynaptic: inhibits NE release; Postsynaptic: hyperpolarizes locus coeruleus neurons

B. Central Sedative Pathway

Binds alpha2A in locus coeruleus -> hyperpolarization, lower NE release -> disinhibits ventrolateral preoptic nucleus (VLPO) -> VLPO releases GABA/galanin -> suppresses arousal centers -> mimics natural non-REM (stage 2) sleep. This differs fundamentally from GABAergic agents (propofol/benzodiazepines) which directly potentiate GABA-A receptors - explaining easy arousability. Analgesic mechanism: dorsal horn alpha2 agonism inhibits substance P, opioid-receptor-independent.

C. Pharmacokinetics

Parameter	Value
Bioavailability (IV)	100%; intranasal ~65%, buccal ~82%, IM ~73%
Protein binding	~94%
Distribution t1/2a	~6 minutes
Elimination t1/2b	~2-2.5 hours
Vdss	~118 L
Clearance	~39 L/hr (high extraction ratio)
Metabolism	Hepatic - glucuronidation + CYP2A6 oxidation
Elimination	Renal ~95% (metabolites), fecal ~4%
Context-sensitive half-time	~4 min (10 min infusion) to ~250 min (8h infusion)

Hepatic impairment significantly prolongs clearance (dose reduction needed); renal impairment has minimal effect on parent drug.

D. Cardiovascular Effects

Phase	Mechanism	Hemodynamic Effect
Biphasic initial (bolus)	Peripheral alpha2B vasoconstriction predominates initially	Transient raised BP, reflex lower HR
Maintenance	Central sympatholysis dominates	Lower HR, lower BP, lower SVR, lower catecholamines

Bradycardia common (caution with beta-blockers/heart block). Reduces MAC and blunts laryngoscopy response. Does NOT cause significant myocardial depression.

E. Respiratory Effects

Key Advantage - Minimal Respiratory Depression

CO2 response curve is largely preserved even at sedative-to-light-anesthetic doses, uniquely suited for awake fiberoptic intubation, sedation during regional anesthesia, and HFNO-assisted sedation.

F. Other Notable Effects

Analgesic/opioid-sparing
Anti-shivering (alpha2B, resets hypothalamic threshold)
Reduces emergence delirium and PACU agitation
Diuresis (inhibits ADH)
No effect on seizure threshold - useful during neurophysiological monitoring

💬 Viva Corner

Q. Why does dexmedetomidine sometimes cause transient hypertension on bolus?

Biphasic effect - rapid bolus first stimulates peripheral alpha2B vasoconstriction before central sympatholysis dominates. Slow administration over 10 min minimizes the pressor phase.

Q. Why does it spare respiratory drive unlike propofol/benzodiazepines?

It acts via the endogenous sleep pathway (locus coeruleus -> VLPO) rather than directly potentiating GABA-A receptors in brainstem respiratory centers, largely preserving CO2 response.

★ Examiner's Pearl

Name the locus coeruleus -> VLPO pathway explicitly. Describe the biphasic CV response with receptor basis. State respiratory drive preservation and tie to awake fiberoptic intubation.

References

Nelson LE et al. Anesthesiology 2003;98:428-436. Weerink MAS et al. Clin Pharmacokinet 2017;56:893-913.

"

lock Protected Clinical Document • Pulse App • Screenshots Strictly Prohibited

QUESTION 160 person Asked by .

bookmark_add

Comprehensive classification of Mapleson systems; performance, FGF requirements, and efficiency of Mapleson A, D and F during spontaneous vs controlled ventilation.

description Clinical Response

"

Q4 · PAPER I · 10 MARKS

Mapleson Breathing Systems — Classification, Performance & FGF Requirements

AIIMS/PGIMER · PAPER I — APPLIED BASIC SCIENCES [10 MARKS]

Comprehensive classification of Mapleson systems; performance, FGF requirements, and efficiency of Mapleson A, D and F during spontaneous vs controlled ventilation.

⚙ Core Concept

Mapleson systems are valveless (semi-open) circuits classified A-F by relative position of the fresh gas inlet, reservoir bag, and APL valve. Efficiency at preventing rebreathing differs dramatically between spontaneous and controlled ventilation.

A. Classification of Mapleson Systems

Type	Configuration	Common Name
A	FGI near bag; APL valve at patient end	Magill attachment
B	FGI near patient end; APL also near patient end	Rarely used
C	Like B, shorter tubing, no corrugated tube	Waters' circuit
D	FGI at patient end; APL valve/bag at machine end	Bain's circuit
E	No bag/valve; FGI at patient end; open-ended tube	Ayre's T-piece
F	E + open-ended reservoir bag distal	Jackson-Rees modification

Mnemonic: efficiency for spontaneous ventilation A > DFE > CB. For controlled ventilation: DFE > BC > A (reverse order).

B. Mapleson A (Magill Attachment)

Mode	FGF Requirement	Mechanism/Efficiency
Spontaneous	~minute volume (50-70 mL/kg/min) - most efficient	Dead-space gas fills tubing first, then alveolar gas vents through APL before fresh gas mixes
Controlled	Very high 2-3x MV - least efficient	Bag compression forces fresh+alveolar gas out via APL before reaching patient; essentially unsuitable for IPPV

C. Mapleson D (and Coaxial Bain Circuit)

Mode	FGF Requirement	Mechanism/Efficiency
Spontaneous	High 2-3x MV (200-300 mL/kg/min) - least efficient	FGI at patient end washes fresh gas toward patient; CO2 washout depends on high flow
Controlled	Much lower ~70 mL/kg/min (min ~4.5 L/min) - most efficient	Positive-pressure to-and-fro bulk flow efficiently flushes CO2; widely used in MRI/remote anesthesia

Bain Circuit-Specific Hazard

Inner-tube (fresh gas) disconnection is dangerous and hard to detect - patient rebreathes through dead space with insidious hypercapnia even though the bag still moves. Pethick's test (occlude patient end, O2 flush, release - Venturi effect should deflate bag if intact) should be performed before use.

D. Mapleson F (Jackson-Rees Modification)

Mode	FGF Requirement	Mechanism/Efficiency
Spontaneous	2-3x MV (~1000 mL + 100-200 mL/kg/min pediatric)	Open-ended bag allows visual/manual assistance, low resistance ideal for pediatrics
Controlled	Similarly high flows; IPPV via occluding bag tail	No valve resistance/dead space - ideal for small children

Why preferred in pediatrics: lightweight, minimal apparatus dead space, very low resistance, direct feel/observation of compliance.

💬 Viva Corner

Q. Why is Mapleson A efficient spontaneously but poor for controlled ventilation?

Spontaneously, exhaled dead-space gas fills the tube first and alveolar gas vents via APL before fresh gas mixing. Under IPPV, bag compression forces fresh gas out via APL before reaching the patient while alveolar gas is retained/rebreathed.

Q. What is Pethick's test?

Checks Bain inner tube integrity: occlude patient end, fill via O2 flush, release - if intact, Venturi effect deflates the bag; if disconnected, the bag stays inflated, detecting a silent, potentially fatal fault.

★ Examiner's Pearl

State the mnemonic ranking explicitly and explain the mechanism for Mapleson A. Always volunteer the Bain inner-tube disconnection hazard.

References

Mapleson WW. Br J Anaesth 1954;26:323-332. Bain JA, Spoerel WE. Can Anaesth Soc J 1972;19:426-435.

"

ENT Anaesthesia — Shared Airway, LASER Safety, Microlaryngoscopy & Post-Tonsillectomy Bleed

A. The Shared Airway3 marks

B. LASER Safety & Microlaryngoscopy4 marks

C. Post-Tonsillectomy Haemorrhage3 marks

ICU Sedation and Analgesia — RASS, ABCDEF Bundle, CAM-ICU & Dexmedetomidine

A. Assessment Tools3 marks

B. Analgosedation & ABCDEF Bundle4 marks

C. ICU Delirium, CAM-ICU & Dexmedetomidine3 marks

Major Trauma — ATLS ABCDE, Damage Control Resuscitation, TXA & Lethal Triad

A. ATLS Primary Survey (ABCDE)3 marks

B. Permissive Hypotension & DCR4 marks

C. The Lethal Triad3 marks

Ophthalmic Anaesthesia — Oculocardiac Reflex, IOP Control, Sub-Tenon's Block & Open Globe

A. Oculocardiac Reflex (OCR)3 marks

B. IOP — Determinants & Anaesthetic Effects3 marks

C. Sub-Tenon's Block & Open Globe4 marks

TIVA & Future — TCI Models, Closed-Loop Anaesthesia & AI in Anaesthesia

A. Pharmacokinetics of TCI — Marsh vs Schnider4 marks

B. TIVA — Advantages, Limitations & Depth Monitoring3 marks

C. Closed-Loop Anaesthesia & Future Directions3 marks

Discuss the physiological regulation of CBF, BBB structure/breakdown in neuro-trauma, ICP factors, ICP-lowering pharmacology, and SjO2 monitoring.

Functional anatomy of the NMJ; mechanism, metabolism, elimination kinetics, TOF/PTC-based dosing, and anaphylaxis/cardiac risk of Sugammadex.

Physical gas laws governing the anesthesia circuit; working principles, compensation systems, pumping/back-pressure effects, and mis-filling hazards of variable-bypass vaporizers.

PK/PD of dexmedetomidine; receptor affinity, central sedative pathways, and cardiovascular/respiratory physiological impacts.

Comprehensive classification of Mapleson systems; performance, FGF requirements, and efficiency of Mapleson A, D and F during spontaneous vs controlled ventilation.

Subcategory Tree

Category Subscription

Anatomical Models

Case Reviews